Nascent Biotech, Inc. (NBIO)
USD 0.01
(44.44%)
USD 0.01
(44.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -249.62 Thousand USD | -214.82% |
| 2023 | 217.4 Thousand USD | 330.27% |
| 2022 | -94.41 Thousand USD | -158.9% |
| 2021 | 160.3 Thousand USD | 18.22% |
| 2020 | 135.59 Thousand USD | 203.14% |
| 2019 | -131.47 Thousand USD | -12.37% |
| 2018 | -116.99 Thousand USD | 9.87% |
| 2017 | -129.8 Thousand USD | 77.36% |
| 2016 | -573.35 Thousand USD | -1105.25% |
| 2015 | -47.57 Thousand USD | 58.21% |
| 2014 | -113.83 Thousand USD | -175.26% |
| 2013 | 151.24 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -249.62 Thousand USD | 49.96% |
| 2024 Q1 | 267.49 Thousand USD | 23.04% |
| 2024 FY | -249.62 Thousand USD | -214.82% |
| 2024 Q3 | -498.85 Thousand USD | 28.63% |
| 2024 Q2 | -698.96 Thousand USD | -361.3% |
| 2023 Q2 | -888.77 Thousand USD | -1001.49% |
| 2023 FY | 217.4 Thousand USD | 330.27% |
| 2023 Q4 | 217.4 Thousand USD | 345.41% |
| 2023 Q3 | -88.59 Thousand USD | 90.03% |
| 2023 Q1 | -80.68 Thousand USD | 14.54% |
| 2022 Q2 | -23.26 Thousand USD | 89.24% |
| 2022 Q3 | 163.69 Thousand USD | 803.62% |
| 2022 FY | -94.41 Thousand USD | -158.9% |
| 2022 Q4 | -94.41 Thousand USD | -157.68% |
| 2022 Q1 | -216.18 Thousand USD | -234.86% |
| 2021 Q3 | 55.12 Thousand USD | 162.67% |
| 2021 Q2 | -87.94 Thousand USD | -133.72% |
| 2021 Q1 | 260.81 Thousand USD | 92.35% |
| 2021 FY | 160.3 Thousand USD | 18.22% |
| 2021 Q4 | 160.3 Thousand USD | 190.82% |
| 2020 Q2 | -5471.00 USD | -1.73% |
| 2020 FY | 135.59 Thousand USD | 203.14% |
| 2020 Q1 | -5378.00 USD | 95.91% |
| 2020 Q4 | 135.59 Thousand USD | 7554.48% |
| 2020 Q3 | -1819.00 USD | 66.75% |
| 2019 Q3 | -103.3 Thousand USD | 6.23% |
| 2019 Q1 | -49.14 Thousand USD | 58.0% |
| 2019 FY | -131.47 Thousand USD | -12.37% |
| 2019 Q2 | -110.17 Thousand USD | -124.2% |
| 2019 Q4 | -131.47 Thousand USD | -27.27% |
| 2018 Q3 | -268.14 Thousand USD | 49.02% |
| 2018 FY | -116.99 Thousand USD | 9.87% |
| 2018 Q2 | -525.96 Thousand USD | -239.46% |
| 2018 Q1 | -154.93 Thousand USD | -19.36% |
| 2018 Q4 | -116.99 Thousand USD | 56.37% |
| 2017 Q1 | -65.22 Thousand USD | 88.62% |
| 2017 Q4 | -129.8 Thousand USD | -42.37% |
| 2017 FY | -129.8 Thousand USD | 77.36% |
| 2017 Q3 | -91.17 Thousand USD | 75.8% |
| 2017 Q2 | -376.81 Thousand USD | -477.74% |
| 2016 Q2 | -42.41 Thousand USD | 10.01% |
| 2016 Q1 | -47.12 Thousand USD | 0.94% |
| 2016 FY | -573.35 Thousand USD | -1105.25% |
| 2016 Q4 | -573.35 Thousand USD | -8787.77% |
| 2016 Q3 | -6451.00 USD | 84.79% |
| 2015 FY | -47.57 Thousand USD | 58.21% |
| 2015 Q1 | 113.83 Thousand USD | 200.0% |
| 2015 Q4 | -47.57 Thousand USD | 79.26% |
| 2015 Q2 | -5557.00 USD | -104.88% |
| 2015 Q3 | -229.39 Thousand USD | -4028.05% |
| 2014 Q4 | -113.83 Thousand USD | 0.0% |
| 2014 FY | -113.83 Thousand USD | -175.26% |
| 2013 FY | 151.24 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -18954.962% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 104.419% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.583% |
| Rebus Holdings, Inc. | 305 Thousand USD | 181.843% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 96.041% |
| Qrons Inc. | 351.42 Thousand USD | 171.03% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 140.108% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.575% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1123.148% |
| Skye Bioscience, Inc. | -5.72 Million USD | 95.637% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 101.584% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 106.062% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 162.118% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.311% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 111.133% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 126.922% |
| Mesoblast Limited | 55.85 Million USD | 100.447% |
| Marizyme, Inc. | 18.56 Million USD | 101.344% |
| Genus plc | 190.6 Million USD | 100.131% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 111.165% |
| Pharming Group N.V. | 109.8 Million USD | 100.227% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 129.017% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 120.564% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 136.709% |
| ContraFect Corporation | -6.02 Million USD | 95.858% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 285.399% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 121.604% |
| IMV Inc. | 7.67 Million USD | 103.254% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 104.537% |
| MultiCell Technologies, Inc. | 90.04 USD | 277332.341% |
| ONE Bio Corp. | 9.04 Million USD | 102.761% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 65.991% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 101.928% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 118.247% |
| Q BioMed Inc. | 4.06 Million USD | 106.148% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.817% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 124.771% |
| Biomind Labs Inc. | 711.4 Thousand USD | 135.088% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.412% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 112.485% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 101.949% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 169.395% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 278.55% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 1356.455% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 111.336% |
| GB Sciences, Inc. | 1.74 Million USD | 114.286% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -35.82% |
| HST Global, Inc. | 96.79 Thousand USD | 357.891% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 221.047% |
| Halberd Corporation | 144.72 Thousand USD | 272.484% |
| Enzolytics Inc. | 981.65 Thousand USD | 125.428% |
| Agentix Corp. | 37.63 Thousand USD | 763.336% |
| Resverlogix Corp. | 6.45 Million USD | 103.869% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 62.914% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.988% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.469% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 103.53% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 109.216% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 97.176% |
| AVAX Technologies, Inc. | -5.9 Million USD | 95.771% |
| Zenith Capital Corp. | 10.06 Thousand USD | 2580.326% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.976% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 224.541% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 110.462% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 251.736% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1262.703% |
| Kadimastem Ltd | -253.1 Thousand USD | 1.376% |
| Helix BioMedix, Inc. | -2.57 Million USD | 90.287% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 101.231% |
| BioStem Technologies, Inc. | 4.47 Million USD | 105.582% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 224.032% |
| LadRx Corporation | -2.03 Million USD | 87.743% |
| Cell Source, Inc. | 9.23 Million USD | 102.704% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 139.3% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 139.3% |
| NovAccess Global Inc. | 2.17 Million USD | 111.459% |
| Affymax, Inc. | -5.59 Million USD | 95.54% |
| Itoco Inc. | 228.3 Thousand USD | 209.336% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 283.559% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 105.036% |
| Mobile Lads Corp. | 484.23 Thousand USD | 151.55% |
| CytoDyn Inc. | 20.26 Million USD | 101.232% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -38481.144% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -2593.255% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 103.239% |
| SYBLEU INC | 473.71 Thousand USD | 152.694% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 105.601% |
| International Stem Cell Corporation | 2.59 Million USD | 109.638% |
| Bioxytran, Inc. | 1.89 Million USD | 113.145% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 499.949% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 111.446% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 107.269% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 102.919% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 132.309% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 80.03% |
| Neutra Corp. | 52.18 Thousand USD | 578.318% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 89.971% |
| PureTech Health plc | -167.19 Million USD | 99.851% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -1.924% |
| IXICO plc | -4.44 Million USD | 94.384% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 101.888% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.455% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Cellectis S.A. | -43.81 Million USD | 99.43% |